On Oct 30, major Wall Street analysts update their ratings for $Tenet Healthcare (THC.US)$, with price targets ranging from $183 to $217.
BofA Securities analyst Joanna Gajuk initiates coverage with a buy rating, and sets the target price at $189.
UBS analyst A.J. Rice maintains with a buy rating, and adjusts the target price from $164 to $217.
Wells Fargo analyst Steve Baxter maintains with a buy rating, and maintains the target price at $195.
RBC Capital analyst Ben Hendrix maintains with a buy rating, and adjusts the target price from $136 to $183.
Truist Financial analyst David S Macdonald maintains with a buy rating, and adjusts the target price from $180 to $190.
Furthermore, according to the comprehensive report, the opinions of $Tenet Healthcare (THC.US)$'s main analysts recently are as follows:
Tenet Healthcare exhibited a robust performance across all segments for the third quarter, with notable strength in the hospital segment and the USPI segment meeting expectations. The company remains focused on prioritizing investments in the USPI segment as its foremost capital allocation, while also continuing to invest in significant hospital growth opportunities, especially after streamlining its hospital portfolio through a series of divestitures.
Tenet Healthcare demonstrated a noteworthy recovery from prior weaknesses in the hospital segment, buoyed by a robust third-quarter performance and an upward revision in guidance. The company's preliminary outlook for 2025 indicates the potential for sustained strong volume trends into the following year, along with ongoing expansion of capacity.
Here are the latest investment ratings and price targets for $Tenet Healthcare (THC.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月30日，多家華爾街大行更新了$泰尼特 (THC.US)$的評級，目標價介於183美元至217美元。
美銀證券分析師Joanna Gajuk首次給予買入評級，目標價189美元。
瑞士銀行分析師A.J. Rice維持買入評級，並將目標價從164美元上調至217美元。
富國集團分析師Steve Baxter維持買入評級，維持目標價195美元。
加皇資本市場分析師Ben Hendrix維持買入評級，並將目標價從136美元上調至183美元。
儲億銀行分析師David S Macdonald維持買入評級，並將目標價從180美元上調至190美元。
此外，綜合報道，$泰尼特 (THC.US)$近期主要分析師觀點如下：
泰尼特在第三季度各業務板塊展現出強勁表現，特別是醫院板塊和USPI板塊表現突出，符合預期。公司繼續專注於將投資重點放在USPI板塊作爲最主要的資本配置，同時繼續投資於重大醫院增長機會，尤其是在通過一系列資產出售優化醫院投資組合之後。
泰尼特展示出在醫院板塊先前弱勢的顯着復甦，得益於強勁的第三季度業績和業績指引的上調。公司對2025年的初步展望表明，有望持續強勁的成交量趨勢延續到明年，同時容量持續擴大。
以下爲今日6位分析師對$泰尼特 (THC.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
